These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 24430235)

  • 1. In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models.
    Jing Y; Zaias J; Duncan R; Russell SJ; Merchan JR
    Gene Ther; 2014 Mar; 21(3):289-97. PubMed ID: 24430235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
    Jing Y; Bejarano MT; Zaias J; Merchan JR
    Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
    Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
    Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.
    Jing Y; Chavez V; Ban Y; Acquavella N; El-Ashry D; Pronin A; Chen X; Merchan JR
    Mol Cancer Res; 2017 Oct; 15(10):1410-1420. PubMed ID: 28679779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
    Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E
    J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host.
    Zhang Z; Hu Z; Gupta J; Krimmel JD; Gerseny HM; Berg AF; Robbins JS; Du H; Prabhakar B; Seth P
    Cancer Gene Ther; 2012 Sep; 19(9):630-6. PubMed ID: 22744210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
    Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
    Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo antitumor activity by dual stromal and tumor-targeted oncolytic measles viruses.
    Jing Y; Chavez V; Khatwani N; Ban Y; Espejo AP; Chen X; Merchan JR
    Cancer Gene Ther; 2020 Dec; 27(12):910-922. PubMed ID: 32231231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
    Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
    Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
    Grossardt C; Engeland CE; Bossow S; Halama N; Zaoui K; Leber MF; Springfeld C; Jaeger D; von Kalle C; Ungerechts G
    Hum Gene Ther; 2013 Jul; 24(7):644-54. PubMed ID: 23642239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocols to Manufacture an Oncolytic Measles Virus-Sensitive Immunocompetent Mouse Model of Medulloblastoma.
    Lal S; Raffel C
    Methods Mol Biol; 2022; 2423():165-177. PubMed ID: 34978698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.
    Hutzen B; Bid HK; Houghton PJ; Pierson CR; Powell K; Bratasz A; Raffel C; Studebaker AW
    BMC Cancer; 2014 Mar; 14():206. PubMed ID: 24646176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
    Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
    Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
    Engeland CE; Grossardt C; Veinalde R; Bossow S; Lutz D; Kaufmann JK; Shevchenko I; Umansky V; Nettelbeck DM; Weichert W; Jäger D; von Kalle C; Ungerechts G
    Mol Ther; 2014 Nov; 22(11):1949-59. PubMed ID: 25156126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic measles virus retargeting by ligand display.
    Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
    Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models.
    Huch M; Gros A; José A; González JR; Alemany R; Fillat C
    Neoplasia; 2009 Jun; 11(6):518-28, 4 p following 528. PubMed ID: 19484141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis.
    Hoffmann D; Bayer W; Wildner O
    Hum Gene Ther; 2007 May; 18(5):435-50. PubMed ID: 17518612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus.
    Bach P; Abel T; Hoffmann C; Gal Z; Braun G; Voelker I; Ball CR; Johnston IC; Lauer UM; Herold-Mende C; Mühlebach MD; Glimm H; Buchholz CJ
    Cancer Res; 2013 Jan; 73(2):865-74. PubMed ID: 23293278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
    Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
    Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
    Galanis E; Atherton PJ; Maurer MJ; Knutson KL; Dowdy SC; Cliby WA; Haluska P; Long HJ; Oberg A; Aderca I; Block MS; Bakkum-Gamez J; Federspiel MJ; Russell SJ; Kalli KR; Keeney G; Peng KW; Hartmann LC
    Cancer Res; 2015 Jan; 75(1):22-30. PubMed ID: 25398436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.